



(51) International Patent Classification:

C07K 16/40 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2022/081121

(22) International Filing Date:

07 December 2022 (07.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/288,174 10 December 2021 (10.12.2021) US
63/350,580 09 June 2022 (09.06.2022) US

(71) Applicant: **OMEROS CORPORATION** [US/US]; 201 Elliott Avenue West, Seattle, WA 98119 (US).

(72) Inventors: **DUDLER, Thomas**; c/o Omeros Corporation, 201 Elliott Avenue West, Seattle, WA 98119 (US). **NOLLERT VON SPECHT, Peter, Kurt**; c/o Omeros Corporation, 201 Elliott Avenue West, Seattle, WA 98119 (US). **YABUKI, Munchisa**; c/o Omeros Corporation, 201 Elliott Avenue West, Seattle, WA 98119 (US). **YASEEN,**


Sadam; c/o Omeros Corporation, 201 Elliott Avenue West, Seattle, WA 98119 (US).

(74) Agent: **GERTZ, Glenda, A.**; Omeros Corporation, 201 Elliott Avenue West, Seattle, WA 98119 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

(54) Title: THERAPEUTIC ANTIBODIES THAT BIND TO THE SERINE PROTEASE DOMAIN OF MASP-2 AND USES THEREOF

**FIG.21**

(57) Abstract: Isolated monoclonal antibodies and antigen-binding fragments thereof are provided that specifically bind, to an epitope within the serine protease domain of human MASP-2. In some embodiments, the antibodies or antigen-binding fragments thereof inhibit lectin pathway complement activation. Also provided are polynucleotides encoding the disclosed monoclonal antibodies or antigen-binding fragments thereof, and cloning vectors or expression cassettes comprising such polynucleotides. Further provided are methods of inhibiting lectin pathway complement activation and methods of treating lectin pathway diseases and disorders.



LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*